NCT00112047 - Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects | Biotech Hunter

Enrollment

517

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

February 28, 2005

Study Completion Date

June 30, 2009

Conditions

HIV Infections

Interventions

DRUG

Emtricitabine (FTC)

Capsule containing 200 mg FTC, taken once daily, for 96 weeks

DRUG

Tenofovir Disoproxil Fumarate (TDF)

Tablet containing 300 mg TDF, taken once daily, for 96 weeks

DRUG

Efavirenz (EFV)

Tablet containing 600 mg EFV, taken once daily, for 96 weeks

DRUG

FTC/TDF

Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144

DRUG

FTC/TDF/EFV

Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240

DRUG

Lamivudine/zidovudine

Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks

Trial Locations (5)

Capital Medical Associates, P.C., Washington D.C.

Jemsek Clinic, Huntersville

Orlando Immunology Center, Orlando

NorthStar Medical Center, Chicago

AIDS Healthcare Foundation Research, Beverly Hills